RARE Ultragenyx Pharmaceutical Inc
$14.74
▼ 2.8%Updated Oct 16, 2:25 PM ET
Report Card
RARE at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.
Key Metrics
Market Cap
—
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
—
Interest Coverage
—
Current Ratio
1.73x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
Not rated
Business Overview
Ultragenyx Pharmaceutical Inc (RARE) is a NASDAQ-listed company in the Biotechnology industry, within the Health Care sector.
In its latest reported year it generated about $673.00M in revenue and posted a net loss of $575.00M.
Our model hasn't rated RARE yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedThe numbers don't show a durable competitive advantage — margins, growth, or returns on capital have been unstable or thin. Great returns are still possible; they just aren't protected.
-102.1% average over the last 3 years
±55582.8 pts around -20091.0% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 0 of 10 years
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Revenue Growth
4Y CAGR
17.6%
Revenue moved from $133.00K in 2016 to $673.00M in 2025, a 158.0% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
—
Operating Margin
-79.5%
Net Margin
-85.4%
ROE
—
Debt Analysis
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 1.7x. Detailed balance-sheet leverage is limited for this name.
Cash Flow Analysis
Operating CF
-$466.00M
Free Cash Flow
-$472.00M
FCF Margin
-70.1%
In the latest year Ultragenyx Pharmaceutical Inc produced about -$466.00M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
RARE trades at n/a trailing earnings. Its valuation ratios aren't loaded yet, so there is no P/E to judge here.
Metrics vs. Sector Range
Where RARE sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How RARE stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
RARE doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.
P/E vs sector
—
median 26.1x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
—
not rated yet
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$3.61 – $6.02
vs. $14.74 today · implied CAGR -25% – -16%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $726.84M | $784.99M | $847.79M | $915.61M | $988.86M |
| Net income | $21.81M | $23.55M | $25.43M | $27.47M | $29.67M |
| EPS | $0.22 | $0.24 | $0.26 | $0.28 | $0.30 |
| Share price (low) | $2.65 | $2.87 | $3.10 | $3.34 | $3.61 |
| Share price (high) | $4.42 | $4.78 | $5.16 | $5.57 | $6.02 |
| CAGR (low–high) | -82% / -70% | -56% / -43% | -41% / -30% | -31% / -22% | -25% / -16% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions. Growth, margin or P/E data is missing for this stock, so some starting values above are placeholders rather than measurements.
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Analyst Ratings
What 26 Wall Street analysts covering RARE recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
RARE's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
RARE — frequently asked questions
Is RARE a good stock to buy?
We don't give buy or sell advice. Review Ultragenyx Pharmaceutical Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does RARE's data come from?
Live price data plus the annual financials in Ultragenyx Pharmaceutical Inc's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.
How is the 5-year projection for RARE calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this RARE analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell RARE. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.